Repeat-dose toxicology evaluation in cynomolgus monkeys of AVI-4658, a phosphorodiamidate morpholino oligomer (PMO) drug for the treatment of duchenne muscular dystrophy

International Journal of Toxicology

Volumn 30, Issue 3, 2011, Pages 313-321

  Sazani, Peter ^a   Ness, Kirk P Van ^a   Weller, Doreen L ^a   Poage, Duane W ^b   Palyada, Kiran ^b   Shrewsbury, Stephen B ^a  

^a AVI BioPharma   (United States)

^b MPI RESEARCH   (United States)

Author keywords

alternative splicing; antisense oligonucleotide; Duchenne muscular dystrophy; exon skipping; morpholino

Indexed keywords

ETEPLIRSEN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BASOPHIL; BLOOD CLOTTING; BODY WEIGHT; CELL GRANULE; CELL VACUOLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TOLERABILITY; DUCHENNE MUSCULAR DYSTROPHY; ELECTROCARDIOGRAPHY; FEMALE; FOOD INTAKE; HAPLORHINI; HEMATOLOGY; HISTOPATHOLOGY; KIDNEY FUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; OPHTHALMOSCOPY; ORGAN WEIGHT; PLASMA CLEARANCE; REPEATED DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXICITY TESTING; TOXICOKINETICS; URINALYSIS;

ANIMALS; BASE SEQUENCE; FEMALE; MACACA FASCICULARIS; MALE; MUSCULAR DYSTROPHY, DUCHENNE; OLIGONUCLEOTIDES;

MACACA FASCICULARIS;

EID: 79960695660     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1177/1091581811403505     Document Type: Article

References (22)

1. Hudziak RM, Barofsky E, Barofsky DF, Weller DL, Huang SB, Weller DD. Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev. 1996 ; 6 (4). 267-272 (Pubitemid 27045903)
2. Crooke ST. Antisense strategies. Curr Mol Med. 2004 ; 4 (5). 465-487 (Pubitemid 38961192)
3. Rayburn ER, Zhang R. Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible?. Drug Discov Today. 2008 ; 13 (11-12). 513-521
4. Iversen PL, Cornish KG, Iversen LJ, Mata JE, Bylund DB. Bolus intravenous injection of phosphorothioate oligonucleotides causes hypotension by acting as alpha(1)-adrenergic receptor antagonists. Toxicol Appl Pharmacol. 1999 ; 160 (3). 289-296 (Pubitemid 29536377)
5. Farman CA, Kornbrust DJ. Oligodeoxynucleotide studies in primates: antisense and immune stimulatory indications. Toxicol Pathol. 2003 ; 31 (suppl). 119-122 (Pubitemid 36169411)
6. Sheehan JP, Lan HC. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex. Blood. 1998 ; 92 (5). 1617-1625 (Pubitemid 28406865)
7. Swayze EE, Siwkowski AM, Wancewicz EV, et al. Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res. 2007 ; 35 (2). 687-700 (Pubitemid 46232083)
8. Arechavala-Gomeza V, Graham IR, Popplewell LJ, et al. Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Hum Gene Ther. 2007 ; 18 (9). 798-810 (Pubitemid 47502846)
9. Sazani P, Weller DL, Shrewsbury SB. Safety pharmacology and genotoxicity evaluation of AVI-4658. Int J Toxicol. 2010 ; 29 (2). 143-156
10. Kinali M, Arechavala-Gomeza V, Feng L, et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol. 2009 ; 8 (10). 918-928
11. Bazett HC. The time relations of the blood-pressure changes after excision of the adrenal glands, with some observations on blood volume changes. J Physiol. 1920 ; 53 (5). 320-339
12. Emery A, Muntoni F Duchenne Muscular Dystrophy. 3 rd ed. Emery A Muntoni F, ed. Oxford: Oxford University Press ; 2003: 26-45.
13. Emery AE. The muscular dystrophies. Lancet. 2002 ; 359 (9307). 687-695 (Pubitemid 34203773)
14. Zhou L, Lu H. Targeting fibrosis in Duchenne muscular dystrophy. J Neuropathol Exp Neurol. 2010 ; 69 (8). 771-776
15. Drachman DB, Toyka KV, Myer E. Prednisone in Duchenne muscular dystrophy. Lancet. 1974 ; 2 (7894). 1409-1412
16. Adcock IM, Caramori G. Cross-talk between pro-inflammatory transcription factors and glucocorticoids. Immunol Cell Biol. 2001 ; 79 (4). 376-384 (Pubitemid 32744283)
17. Dubrovsky AL, Angelini C, Bonifati DM, Pegoraro E, Mesa L. Steroids in muscular dystrophy: where do we stand?. Neuromuscul Disord. 1998 ; 8 (6). 380-384 (Pubitemid 28388936)
18. Merlini L, Cicognani A, Malaspina E, et al. Early prednisone treatment in Duchenne muscular dystrophy. Muscle Nerve. 2003 ; 27 (2). 222-227 (Pubitemid 36169334)
19. Crooke ST Antisense Drug Technology: Principles, Strategies, and Applications. 2 nd ed. Boca Raton: CRC Press ; 2008 :
20. Henry SP, Novotny W, Leeds J, Auletta C, Kornbrust DJ. Inhibition of coagulation by a phosphorothioate oligonucleotide. Antisense Nucleic Acid Drug Dev. 1997 ; 7 (5). 503-510 (Pubitemid 27491373)
21. Henry SP, Templin MV, Gillett N, Rojko J, Levin AA. Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1. Toxicol Pathol. 1999 ; 27 (1). 95-100 (Pubitemid 29075751)
22. Bonventre JV, Vaidya VS, Schmouder R, Feig P, Dieterle F. Next-generation biomarkers for detecting kidney toxicity. Nat Biotechnol. 2010 ; 28 (5). 436-440